# Crinetics Pharmaceuticals (CRNX) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/CRNX
## Company Profile
- Ticker: CRNX
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Rare Disease, Endocrinology
## Stock Data
- Close: 83.92 USD
- Market cap: 3438405182.88 USD
- Last updated: 2026-08-06
## Business Overview
### Endocrine-Focused Pharmaceuticals
Crinetics Pharmaceuticals discovers, develops and commercializes therapies for endocrine diseases and endocrine-related tumors, with core expertise in small molecules targeting G-protein-coupled receptors.
### PALSONIFY
PALSONIFY, or paltusotine, is an oral somatostatin receptor type 2 agonist commercialized for acromegaly. It is designed to provide an oral alternative to injected peptide treatments.
### Congenital Adrenal Hyperplasia
Crinetics is also developing therapies for congenital adrenal hyperplasia, including a pediatric program being evaluated in the Phase 2/3 BALANCE-CAH study.
## Why The Stock Is Moving

As of Aug 6, 2026, CRNX was little changed and closed at $83.92. No new same-company headline was identified in the current news window.

## Future Catalysts

- Crinetics's catalysts are paltusotine in acromegaly and atumelnant in endocrine disease, where the next clinical and regulatory steps can keep the endocrine story moving. The company is still building toward a broader hormone-franchise.

## Recent News
- 2026-08-03 20:05 EST — [Crinetics Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update](https://biopharmsignal.com/news/CRNX/crinetics-pharmaceuticals-reports-second-quarter-2026-financial-results-and-prov-88f72dc1) — Source: Crinetics Pharmaceuticals
- 2026-06-30 20:05 EST — [Crinetics Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 4, 2026](https://biopharmsignal.com/news/CRNX/crinetics-pharmaceuticals-to-report-second-quarter-2026-financial-results-on-aug-4b8a9657) — Source: Crinetics Pharmaceuticals
- 2026-06-14 20:30 EST — [Crinetics Presents Full Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) in Oral Presentation at ENDO 2026](https://biopharmsignal.com/news/CRNX/crinetics-presents-full-results-from-phase-2-trial-of-atumelnant-in-congenital-a-c1c2be50) — Source: Crinetics Pharmaceuticals
- 2026-06-14 18:45 EST — [Crinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY™ (paltusotine) Provides Durable, Consistent Acromegaly Control](https://biopharmsignal.com/news/CRNX/crinetics-presents-long-term-data-at-endo-2026-confirming-palsonify-paltusotine--eaa37cc2) — Source: Crinetics Pharmaceuticals
- 2026-06-02 20:05 EST — [Crinetics and Leading Patient Groups Launch ‘Everyday Advocacy’ Initiative to Empower People Across Endocrine Disease Communities](https://biopharmsignal.com/news/CRNX/crinetics-and-leading-patient-groups-launch-everyday-advocacy-initiative-to-empo-3a497246) — Source: Crinetics Pharmaceuticals